pharmacodynamics – mycolab.ai

Drug–drug interactions involving classic psychedelics: A systematic review

mycolabadmin

This review examined how psychedelic drugs like LSD and psilocybin interact with other medications people might be taking. Researchers found that certain psychiatric medications like antipsychotics can block the effects of psychedelics, while other drugs may enhance them. The study highlights the importance of understanding these interactions for safe therapeutic use of psychedelics in clinical settings.

Editorial: Raising the bar: advancing therapeutic strategies for fighting communicable and noncommunicable diseases

mycolabadmin

Scientists are developing new ways to fight dangerous infections caused by bacteria, viruses, and drug-resistant pathogens. Recent discoveries include safer uses of existing drugs, better dosing strategies tailored to individual patients, and effective combination therapies that reduce antibiotic resistance. These advances represent important progress in treating serious infectious diseases like COVID-19, tuberculosis, and bacterial infections.

The therapeutic potential of microdosing psychedelics in depression

mycolabadmin

This review examines whether taking very small doses of psychedelic drugs like LSD and psilocybin might help treat depression. While users report benefits and some studies show subtle positive effects on mood and thinking, scientists have not yet confirmed whether microdosing actually works as a depression treatment. More research with depressed patients is needed to understand if this approach is truly helpful and safe for regular use.

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework

mycolabadmin

Psychedelic drugs like LSD and psilocybin show promise in treating depression with effects lasting months after single doses. However, scientists debate whether the hallucinations and mystical experiences these drugs produce are necessary for their healing effects. This review proposes a framework to test whether lower doses without hallucinations might still provide antidepressant benefits, similar to how anesthesia-administered ketamine works without the patient’s awareness.

Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians

mycolabadmin

This review examines the safety of psilocybin therapy for treating anorexia nervosa, a serious eating disorder with limited treatment options. The authors analyze how psilocybin’s common side effects (like increased heart rate, nausea, and dizziness) interact with medical complications already present in people with anorexia. Based on early clinical trials, they conclude that psilocybin can be safely used in this population with proper medical screening and monitoring protocols tailored to their specific vulnerabilities.

Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring

mycolabadmin

Researchers tested whether psilocybin could help postpartum depression in mice, but found it actually made things worse for both mothers and their babies. While psilocybin normally reduces depression and anxiety, it had the opposite effect during the postpartum period, making mothers more anxious and disrupting their care of pups. Babies exposed to psilocybin through breastfeeding or direct exposure developed anhedonia (inability to feel pleasure) as adults. These findings suggest that the postpartum period may be a particularly vulnerable time for psychedelic use, and more research is needed before considering these drugs for postpartum depression treatment.

Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives

mycolabadmin

This review examines how doctors treat serious fungal infections and the growing problem of fungi becoming resistant to medications. The authors discuss different antifungal drugs, how they work, and why some fungi are becoming harder to treat. They emphasize that controlling fungal resistance requires coordinated efforts across hospitals, farms, and communities, especially since some agricultural pesticides are creating resistant strains that spread to sick patients.

Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

mycolabadmin

This study reviews how a fungal medication called liposomal amphotericin B is used to prevent serious fungal infections in children with weakened immune systems, particularly those with blood cancers or who have had bone marrow transplants. The researchers found that this medicine prevents infections in about 93% of children, though it does cause side effects like low potassium levels in about 23% of patients. However, the study shows that current use of this medicine is quite varied and more high-quality research is needed to determine the best dosing approach.

Introduction to XIV updating course of antimicrobials and infectious diseases

mycolabadmin

Healthcare professionals gathered at a major conference in Madrid to learn about the latest advances in treating infections caused by antibiotic-resistant bacteria and other pathogens. The course highlighted new antibiotic combinations that work against previously untreatable infections, faster ways to identify infections in emergency rooms and intensive care units, and modern treatment strategies based on scientific evidence. Speakers emphasized the importance of using antibiotics wisely, using personalized medicine approaches, and collaborating between laboratory scientists and clinicians to improve patient outcomes.

A zinc-chelating cyclic alkyl polyamine compound is efficient and safe in a murine model of multidrug-resistant Candida auris infection

mycolabadmin

Researchers tested a new drug called APC6 that works by trapping zinc, which fungi need to survive. In mouse studies of a dangerous resistant fungus called Candida auris, APC6 saved all treated mice while most untreated mice died. The drug also reduced fungal infections in organs without causing serious side effects, suggesting it could become a new treatment option for serious fungal infections resistant to current medicines.

Research Keyword: pharmacodynamics